Difference between revisions of "Consolidation of Biotech Industry"
(Daniel2 moved to Continuously growing demand for new medical applications) |
|||
| Line 1: | Line 1: | ||
==Description== | |||
The Biotech industry has seen a large number of start-up companies, and funding for R&D projects has been available from governments as well as from private sources. However, if Biotech companies are not able to deliver on their promises, funding will eventually drain. The companies that have not managed to create money generating products (or research) will face difficulties. The situation can very well be compared to the dot.com situation in the beginning of the millennium, which led to a major consolidation of the internet industry. | |||
==Enablers== | |||
• Start-ups running out of money<br> | |||
• Big pharmaceuticals trying to fill up their product pipelines<br> | |||
• Markets getting more mature<br> | |||
• Falling profitability of Drug Market<br> | |||
• Patents running out<br> | |||
• Cost pressure<br> | |||
==Inhibitors== | |||
• Lower Cost of innovations (niches) <br> | |||
• Lower entry barriers (more and more basic research available) <br> | |||
• Cheaper skilled labour e.g. in Emerging Markets<br> | |||
==Paradigms== | |||
Biotech is an industry like anyone else<br> | |||
==Experts:== | |||
<br> | |||
==Timing:== | |||
<br> | |||
==Web Resources:== | |||
Latest revision as of 13:40, 2 December 2005
Description
The Biotech industry has seen a large number of start-up companies, and funding for R&D projects has been available from governments as well as from private sources. However, if Biotech companies are not able to deliver on their promises, funding will eventually drain. The companies that have not managed to create money generating products (or research) will face difficulties. The situation can very well be compared to the dot.com situation in the beginning of the millennium, which led to a major consolidation of the internet industry.
Enablers
• Start-ups running out of money
• Big pharmaceuticals trying to fill up their product pipelines
• Markets getting more mature
• Falling profitability of Drug Market
• Patents running out
• Cost pressure
Inhibitors
• Lower Cost of innovations (niches)
• Lower entry barriers (more and more basic research available)
• Cheaper skilled labour e.g. in Emerging Markets
Paradigms
Biotech is an industry like anyone else
Experts:
Timing: